BioMarin Pharmaceutical Inc. (BM8.F)
| Previous close | 62.10 |
| Open | 61.64 |
| Bid | 63.08 x 2300 |
| Ask | 63.18 x 2200 |
| Day's range | 61.64 - 62.30 |
| 52-week range | 61.64 - 90.52 |
| Volume | |
| Avg. volume | 50 |
| Market cap | 11.992B |
| Beta (5Y monthly) | 0.31 |
| PE ratio (TTM) | 51.92 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
BioMarin to Present Data Underscoring Sustained Positive Impact of VOXZOGO® (vosoritide) on Health-Related Quality of Life, Growth and Maintenance of Bone Strength in Children with Achondroplasia at 2024 International Skeletal Dysplasia Society Meeting
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that positive data from the CANOPY clinical program evaluating VOXZOGO® (vosoritide) in children with achondroplasia and other genetic skeletal conditions will be presented at the 16th International Skeletal Dysplasia Society meeting (ISDS) in Madrid, Sept. 18-21, 2024. These results include data showing that children with achondroplasia treated with VOXZOGO experienced meaningful improvements beyond height, such as in health-related qu
- PR Newswire
BioMarin Holds Investor Day; Provides New Corporate Strategy and Introduces 2027 Financial Guidance
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) hosted an Investor Day earlier today, where President and Chief Executive Officer Alexander Hardy and other members of BioMarin's leadership team provided an overview of the company's new corporate strategy to deliver sustained value creation and introduced longer-term Total Revenue and Non-GAAP Operating Margin guidance. A copy of the presentation and a replay of the webcast are available at investors.biomarin.com.
- PR Newswire
BioMarin to Host Investor Day Today at 10:30 a.m. Eastern Time
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) will host its Investor Day today in New York. The event begins at 10:30 a.m. Eastern Time and can be accessed virtually here.
